62,060 Edwards Lifesciences Corporation $EW Shares Sold by Investment House LLC

Investment House LLC reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 52.3% in the 3rd quarter, Holdings Channel reports. The firm owned 56,715 shares of the medical research company’s stock after selling 62,060 shares during the period. Investment House LLC’s holdings in Edwards Lifesciences were worth $4,896,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in EW. NorthRock Partners LLC boosted its holdings in shares of Edwards Lifesciences by 1.0% in the second quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock valued at $1,465,000 after acquiring an additional 153 shares during the period. Elevation Wealth Partners LLC increased its holdings in shares of Edwards Lifesciences by 24.8% in the 3rd quarter. Elevation Wealth Partners LLC now owns 779 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 155 shares during the period. Plan A Wealth LLC increased its holdings in shares of Edwards Lifesciences by 3.0% in the 3rd quarter. Plan A Wealth LLC now owns 5,460 shares of the medical research company’s stock valued at $471,000 after acquiring an additional 158 shares during the period. Premier Path Wealth Partners LLC increased its holdings in shares of Edwards Lifesciences by 4.4% in the 1st quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company’s stock valued at $311,000 after acquiring an additional 162 shares during the period. Finally, Ferguson Wellman Capital Management Inc. raised its position in Edwards Lifesciences by 0.7% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 27,077 shares of the medical research company’s stock valued at $2,168,000 after purchasing an additional 185 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In related news, VP Annette Brüls sold 2,644 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Daniel Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,045 shares of company stock worth $451,596 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of EW opened at $90.15 on Friday. The stock has a market capitalization of $51.91 billion, a P/E ratio of 51.81, a P/E/G ratio of 2.32 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a 1 year low of $74.66 and a 1 year high of $96.29. The company’s fifty day moving average is $88.10 and its two-hundred day moving average is $86.60.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the business earned $0.67 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on EW shares. Piper Sandler reiterated an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. The Goldman Sachs Group lifted their price objective on shares of Edwards Lifesciences from $98.00 to $102.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Robert W. Baird decreased their target price on shares of Edwards Lifesciences from $94.00 to $90.00 and set a “neutral” rating for the company in a research note on Thursday, October 15th. Wall Street Zen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Finally, Sanford C. Bernstein boosted their price target on Edwards Lifesciences from $96.00 to $99.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.